BR0312615A - Compostos úteis como inibidores de metaloproteinases - Google Patents

Compostos úteis como inibidores de metaloproteinases

Info

Publication number
BR0312615A
BR0312615A BR0312615-3A BR0312615A BR0312615A BR 0312615 A BR0312615 A BR 0312615A BR 0312615 A BR0312615 A BR 0312615A BR 0312615 A BR0312615 A BR 0312615A
Authority
BR
Brazil
Prior art keywords
compounds useful
metalloproteinase inhibitors
alkenyl
compound
useful
Prior art date
Application number
BR0312615-3A
Other languages
English (en)
Inventor
Burrows
Jeremy
Nicholas
Tucker
Howard
Brown
Simon
James
Patel
Ian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0312615A publication Critical patent/BR0312615A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTOS úTEIS COMO INIBIDORES DE METALOPROTEINASES". A presente invenção se refere a um composto de fórmula (1), onde B é C~ 2~-~ 4~-alquenila ou C~ 2~-~ 4~-alquinila opcionalmente substituídos; o referido composto é de utilidade no processo de inibição de uma ou mais metaloproteinases, em particular da TACE.
BR0312615-3A 2002-07-13 2003-07-09 Compostos úteis como inibidores de metaloproteinases BR0312615A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0216382.2A GB0216382D0 (en) 2002-07-13 2002-07-13 Compounds
PCT/GB2003/002985 WO2004006927A2 (en) 2002-07-13 2003-07-09 Sulphonylpiperidine derivatives containing an alkenyl or alkynly moiety for use as matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BR0312615A true BR0312615A (pt) 2005-04-19

Family

ID=9940462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312615-3A BR0312615A (pt) 2002-07-13 2003-07-09 Compostos úteis como inibidores de metaloproteinases

Country Status (16)

Country Link
US (1) US20060063783A1 (pt)
EP (1) EP1531821A2 (pt)
JP (1) JP2006502990A (pt)
CN (1) CN1668302A (pt)
AU (1) AU2003246933A1 (pt)
BR (1) BR0312615A (pt)
CA (1) CA2492251A1 (pt)
GB (1) GB0216382D0 (pt)
IL (1) IL166011A0 (pt)
IS (1) IS7656A (pt)
MX (1) MXPA05000517A (pt)
NO (1) NO20050764L (pt)
PL (1) PL375361A1 (pt)
RU (1) RU2004139043A (pt)
WO (1) WO2004006927A2 (pt)
ZA (1) ZA200500210B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431285B1 (en) 2001-09-07 2009-01-07 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
HUE030114T2 (en) 2010-07-08 2017-04-28 Kaken Pharma Co Ltd N-hydroxyformamide derivatives and pharmaceutical compositions containing them
AU2011303013B2 (en) * 2010-09-17 2014-08-21 Kaken Pharmaceutical Co., Ltd. Composition for maintaining platelet function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100152A3 (en) * 1997-11-12 2002-07-29 Darwin Discovery Ltd Cambridge Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity, pharmaceutical compositions containing them and their use
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
EP1157021A1 (en) * 1999-02-08 2001-11-28 G.D. SEARLE & CO. Sulfamato hydroxamic acid metalloprotease inhibitor

Also Published As

Publication number Publication date
WO2004006927A3 (en) 2004-03-25
JP2006502990A (ja) 2006-01-26
MXPA05000517A (es) 2005-03-23
AU2003246933A1 (en) 2004-02-02
CA2492251A1 (en) 2004-01-22
NO20050764L (no) 2005-02-11
CN1668302A (zh) 2005-09-14
ZA200500210B (en) 2005-11-02
PL375361A1 (en) 2005-11-28
EP1531821A2 (en) 2005-05-25
GB0216382D0 (en) 2002-08-21
RU2004139043A (ru) 2005-10-10
IS7656A (is) 2005-01-20
IL166011A0 (en) 2006-01-15
US20060063783A1 (en) 2006-03-23
WO2004006927A2 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
BR0207985A (pt) Inibidores de metaloproteinase
BR0207984A (pt) Inibidores de metaloproteinase
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
BRPI0615223A2 (pt) inibidores das serina proteases
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
DK1485359T3 (da) Natriumkanalblokkere
MX2009009540A (es) Inhibidores de metaloproteasa que contienen una porcion heterociclica.
NO20054970L (no) Arylsubstituerte byrazolforbindelser anvendbare som kinaseinhibitorer
BRPI0413973A (pt) compostos
BRPI0606379A2 (pt) triazolftalazinas
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
NO20054787D0 (no) Indenderivater som farmasotiske midler
ATE553077T1 (de) Peptidaseinhibitoren
ATE501103T1 (de) Organische verbindungen
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
BR0313969A (pt) Inibidores de oxitocina
NO20055657L (no) Nye bioisostaererav aktinonin
BRPI0512558A (pt) compostos quìmicos
ATE443044T1 (de) Tace inhibitoren
BR0108501A (pt) Compostos de n-hidróxiformamidas substituìdos por piperidina e piperazina como agentes inibidores de metaloproteinase

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]